Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Dec;11(12):403-406.
doi: 10.14740/jmc3588. Epub 2020 Oct 21.

A COVID-19 Case Complicated by Candida dubliniensis and Klebsiella pneumoniae-Carbapenem-Resistant Enterobacteriaceae

Harith Alataby  1 , Francis Atemnkeng  1 , Sandeep S Bains  1 , Foma M Kenne  1 , Keith Diaz  1 , Jay Nfonoyim  1
Affiliations
Case Reports

A COVID-19 Case Complicated by Candida dubliniensis and Klebsiella pneumoniae-Carbapenem-Resistant Enterobacteriaceae

Harith Alataby et al. J Med Cases. 2020 Dec.

Abstract

There has been increasing evidence of co-infections with coronavirus disease 2019 (COVID-19) pneumonia, which increases the severity of the disease. Organisms such as Klebsiella pneumoniae and Streptococcus pneumoniae have been previously isolated. We present a case of a COVID-19 patient treated with baricitinib and dexamethasone who later developed Klebsiella pneumoniae-carbapenem-resistant Enterobacteriaceae (CRE) and Candida dubliniensis bloodstream infections, treated with meropenem/vaborbactam and micafungin, respectively. These infections are exceedingly rare and are mostly reported in immunosuppressed patients. The finding of these bloodstream infections raises concerns on the cause of immunosuppression in this patient infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) treated with baricitinib and dexamethasone. There has been no report so far of COVID-19 associated with these co-infections.

Keywords: Bacteremia; Baricitinib; COVID-19; Candidemia; Dexamethasone.

PubMed Disclaimer

Conflict of interest statement

None to declare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wang Y, Liao B, Guo Y, Li F, Lei C, Zhang F, Cai W. et al. Clinical characteristics of patients infected with the novel 2019 coronavirus (SARS-Cov-2) in Guangzhou, China. Open Forum Infect Dis. 2020;7(6):ofaa187. doi: 10.1093/ofid/ofaa187. - DOI - PMC - PubMed
    1. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020;81(2):318–356. doi: 10.1016/j.jinf.2020.04.017. - DOI - PMC - PubMed
    1. Cingolani A, Tummolo AM, Montemurro G, Gremese E, Larosa L, Cipriani MC, Pasciuto G. et al. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab. Infection. 2020;48(5):767–771. doi: 10.1007/s15010-020-01476-7. - DOI - PMC - PubMed
    1. Titanji BK, Farley MM, Mehta A, Connor-Schuler R, Moanna A, Cribbs SK, O'Shea J. et al. Use of Baricitinib in Patients with Moderate and Severe COVID-19. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa879. - DOI - PMC - PubMed
    1. Cuzon G, Ouanich J, Gondret R, Naas T, Nordmann P. Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. Antimicrob Agents Chemother. 2011;55(5):2420–2423. doi: 10.1128/AAC.01452-10. - DOI - PMC - PubMed

Publication types

LinkOut - more resources